Repros Thera. Announces That Proellex Significantly Reduced Pain In A U.S. Phase 2 Clinical Trial In Women With ... (Medical News Today) PDF Print

Repros Therapeutics Inc. (NasdaqGM:RPRX) released positive results of its recently completed U.S. Phase 2 Proellex endometriosis trial. Proellex is an oral progesterone receptor modulator. This analysis will be used as the basis for a request for an "End of Phase II Meeting" with the FDA.

read more

 
Share |
Copyright © 2024 Global Dialysis. All Rights Reserved.